월경전불쾌장애의 약물치료 3상 임상 연구 메타분석PHARMACOTHERAPY FOR PREMENSTRUAL DYSPHORIC DISORDER: A META-ANALYSIS OF PHASE 3 TRIALS
- Other Titles
- PHARMACOTHERAPY FOR PREMENSTRUAL DYSPHORIC DISORDER: A META-ANALYSIS OF PHASE 3 TRIALS
- Authors
- 염선경; 유민지; 박나윤; 김성민; 이경욱; 박현태; 신정호; 허준용; 김선행; 김탁
- Issue Date
- 2012
- Publisher
- 대한산부인과학회
- Keywords
- Premenstrual syndrome; Drug therapy; Meta-analysis; Clinical trial; phase 3; 월경전불쾌장애 약물치료; 메타분석; 3상 임상 연구
- Citation
- Obstetrics & Gynecology Science, v.55, no.03, pp.143 - 147
- Indexed
- KCI
- Journal Title
- Obstetrics & Gynecology Science
- Volume
- 55
- Number
- 03
- Start Page
- 143
- End Page
- 147
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/109898
- ISSN
- 2287-8580
- Abstract
- Premenstrual dysphoric disorder (PMDD) is a common condition that temporarily, but repetitively affects patient’s global function.
Patients and physicians alike are often uncertain whether prescription medication for PMDD is suffi ciently effective. The primary objective of this analysis is signal detection in effi cacy of pharmacological treatments in PMDD. Secondary objective is to review which symptoms are likely to respond to which medications. The review included otherwise healthy women with clinician confi rmed diagnosis of PMDD who participated in phase 3 clinical trials for the treatment of PMDD. Twelve pair-wise comparisons of drug and placebo for 2,420 patients with PMDD were performed. Oral contraceptives and selective serotonin receptor inhibitor were effective in alleviating symptoms of PMDD compared to placebo. Both Intermittent and continuous administration were more effective than placebo. This meta-analysis provides a signal that pharmacological treatment of PMDD is effective
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
- Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.